Kissei Pharmaceutical Partners With Reborna Biosciences for Drug Discovery in Genetic Rare Diseases
Kissei Pharmaceutical (TYO:4547) and Reborna Biosciences have signed a research collaboration agreement for drug discovery in genetic rare diseases, according to a Tokyo Stock Exchange filing on Monday.
The collaboration will use Reborna's RNA-targeting small molecule drug discovery technology.
Kissei will provide upfront payments, research expenses, milestone payments, and royalties, and retain global development and commercialization rights for successful compounds.
Price (JPY): $3560.00, Change: $+20, Percent Change: +0.56%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.